CTIS2023-504482-23-00招募中1 期
Immune response to the recombinant Zoster Vaccine in people living with HIV over 50 years of age compared to non-HIV age- and gender-matched controls - Shingr'HIV - CHUBX 2022/40
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 225
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •For PLWH: Be registered in the SHCS or in the ANRS CO3 Aquitaine Cohort, For PLWH + Controls : Age >50 YOA, For PLWH: Time since cART initiation > 10 years, For PLWH + Controls : Not already vaccinated with RZV, For PLWH: HIV viral load <50 copies/ml (within 6 months from the last blood sampling), For PLWH + Controls : Informed consent as documented by signature, For PLWH + Controls : (France) : Person affiliated with or beneficiary of the French social security scheme
排除标准
- •Ongoing signs of febrile or non-febrile infection at the time of the first vaccination, Participation in another study with investigational drug within the 30 days preceding and during the present study, Administration of immunoglobulins or any blood products within 3 months preceding the first dose of vaccine or planned administration during the study period, (France) Patient governed by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent)., Immunosuppression from the following: Current malignant neoplasm; primary immunodeficiency; recent (<2 years) solid or bone-marrow transplant or any transplant still requiring immunosuppressive therapy; Intake of drugs which suppress the immune system (e.g. glucocorticoids for a long time [an equivalent dose of prednisone >20 mg/day > 3 months], monoclonal antibodies, cytostatics, biological products, etc.) within 6 months before screening, Having received a vaccine in the last month or is expected to receive a vaccine in the next month, Having received a shingles vaccine within one year, Presented with herpes zoster in the previous year, Contra-indication to RZV due to hypersensitivity to the active substances or to any of the excipients, Hospitalized patients, Unable to provide informed consent or inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant
研究者
相似试验
尚未招募
不适用
Immunogenicity of a recombinant zoster vaccine (RZV) against herpes zoster (HZ) in adults with rheumatic diseases (SECTORED)DRKS00027579St. Elisabeth Gruppe GmbH Katholische Kliniken Rhein-Ruhr150
招募中
4 期
Immune response to adjuvanted recombinant zoster vaccine in Japanese RA patients treated with upadacitinibRheumatoid arthritisJPRN-jRCTs051220105Watanabe Ryu69
招募中
Unknown
Safety of Recombinant Zoster Vaccine in Patients with Inflammatory Bowel DiseaseInflammatory bowel syndromeJPRN-UMIN000052579Juntendo University50
进行中（未招募）
4 期
Immune Response of Shingrix Vaccine in People Living With HIV (> 50 y.o.) Compared to Age-matched ControlsRZV Vaccine (Shingrix ®)NCT05575830Calmy Alexandra225
招募中
4 期
Immunogenicity of the Recombinant Zoster Vaccine in Multiple Sclerosis PatientsShinglesZosterNCT05596526Prof Patrice Lalive100